Semax vs Selank: Differences, Evidence, and the Amidate Variants Explained

Semax and Selank are often mentioned in the same breath, but they do nearly opposite things — Semax sharpens focus, Selank eases anxiety. Both are Russian intranasal peptides, and both now sell mostly as "amidate" variants that promise more. Here is how they differ, and what the evidence supports.

Semax vs Selank at a glance

Semax and Selank are both synthetic heptapeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, both delivered intranasally, and both studied largely in Russian-language research — but they were built from different parent molecules to do different jobs. Semax descends from a fragment of adrenocorticotropic hormone (ACTH) and skews stimulating and pro-cognitive; Selank descends from the immune peptide tuftsin and skews calming and anti-anxiety. They belong to the same broad cognitive and neuroprotection category but occupy opposite ends of it.

That opposite-ends relationship is the single most useful thing to understand before comparing them, because it reframes the question. People often ask which peptide is "better," but Semax and Selank are not really competitors chasing the same outcome — one is reached for when the goal is alertness and mental sharpness, the other when the goal is reduced stress and anxiety. The more honest framing is which tool fits which goal, and whether the popular "amidate" versions of each actually deliver on what their marketing claims. The table below orients the core differences before the deeper comparison.

What is Semax?

Semax is a synthetic analog of an ACTH fragment — the melanocortin core sequence Met-Glu-His-Phe, extended with a Pro-Gly-Pro tail that protects it from rapid enzymatic breakdown. Its best-documented action is a rapid increase in brain-derived neurotrophic factor (BDNF) and nerve growth factor expression, alongside effects on the melanocortin and dopaminergic systems. The result is a profile users describe as stimulating and focus-sharpening, and it has been studied in cognitive, attention, and stroke-recovery contexts. In Russia it is a registered medicine; elsewhere it is an unapproved research compound.

The mechanistic evidence here is reasonably substantial within its research tradition. Transcriptomic work by Kolomin and colleagues at the Institute of Molecular Genetics documented that a single intranasal dose shifts the expression of hundreds of genes in rodents, most consistently in neurotrophin and synaptic-plasticity pathways, and earlier mechanistic work by Ashmarin and colleagues established the melanocortin-system framing. The important caveat, which applies to Selank equally, is that this literature is concentrated in Russian research groups with limited independent Western replication — a reason to treat the findings as substantive but not broadly confirmed. The full mechanism is covered in Peptigrity's Semax science article, and the compound's live data sits on the Semax compound page.

What is Selank?

Selank is a synthetic analog of tuftsin, a natural immune-modulating peptide, built as a heptapeptide for stability. Its defining property is anxiolytic activity: it modulates GABAergic and serotonergic signaling and inhibits the enzymes that break down enkephalins, producing a calming effect. What makes it notable is what it reportedly does not do — unlike benzodiazepines, the Russian research describes Selank as reducing anxiety without sedation, cognitive impairment, or dependence. Like Semax, it is a registered medicine in Russia and an unapproved research compound in the West.

That benzodiazepine contrast is the heart of Selank's appeal, but it deserves the same evidentiary caution as Semax. The claim that an anxiolytic works without the tolerance and withdrawal that define the benzodiazepine class is a significant one, and the evidence supporting it comes largely from the same single-country research base rather than from large independent trials. It is a genuinely interesting profile that has not been broadly validated outside its originating tradition. The mechanism and the anxiety research are detailed in Peptigrity's Selank science article, with current data on the Selank compound page.

How they differ — mechanism and effect

The core difference is directional: Semax pushes toward stimulation and cognition, Selank toward calm. Semax works largely through neurotrophic (BDNF/NGF) and dopaminergic mechanisms that users experience as sharper focus and mental energy, while Selank works through GABAergic and serotonergic mechanisms experienced as reduced anxiety and a steadier mood. Because they engage substantially different systems, they are usually framed as complementary rather than competing — and some researchers deliberately pair low amounts of each to pursue a focused-but-calm state rather than choosing between them.

This complementarity is why "Semax versus Selank" can be a slightly misleading way to put it. The two are not interchangeable, and they are not ranked on a single scale where one wins. A more accurate mental model is two adjacent tools: reach for the Semax family when the research interest is cognitive performance or neuroprotection, and the Selank family when it is anxiety or stress. The table below maps the practical contrast — and the more consequential question for most buyers is not which peptide, but which form of each, since the market is now dominated by modified "amidate" versions.

The amidate variants explained (N-Acetyl Semax/Selank Amidate)

Most buyers land here, because the Western market is dominated not by plain Semax and Selank but by their modified forms: N-Acetyl Semax Amidate (NASA) and N-Acetyl Selank Amidate. The modification is identical in both — an acetyl group is added to the peptide's N-terminus and an amide group to its C-terminus. The rationale is real, established peptide chemistry: peptides are degraded from each end by exopeptidase enzymes, and capping both termini makes the molecule more resistant to breakdown, extending how long it persists. Proponents also argue the changes improve blood-brain-barrier penetration.

What matters for interpreting these variants is a distinction the marketing tends to blur. The amidate forms are modified versions of the same sequence — they are not a separate peptide family, and the acetylation and amidation do not automatically make them identical to the parent in mechanism, potency, or how their research should be read. They are best understood as engineered-for-stability analogs of Semax and Selank, with genuinely different molecular weights and chemistry from their parents. That last point becomes important for verification later, because a different molecular weight is exactly what distinguishes the amidate from the parent in a lab test. The table summarizes the relationship.

Do the amidate variants actually work better?

This is the question the marketing answers too confidently. The stability rationale is legitimate — capping the peptide's ends genuinely slows enzymatic degradation — but two things should temper the "stronger and longer-lasting" claims. First, the published literature is overwhelmingly on the parent peptides: Semax and Selank are the better-established compounds in the research record, and the amidate variants inherit that credibility without the same direct human evidence. Buying the amidate because it seems like the "researched" version gets this backward — the research is largely on the plain peptides.

Second, the specific numbers attached to the variants do not have the backing their precision implies. Widely repeated figures — that the amidate is "three to four times more potent," or has a half-life of "two to ten hours" versus the parent's shorter window — trace to vendor pages and community discussion rather than robust independent human pharmacokinetic studies. They may turn out to be roughly right, but they should be read as estimates, not established facts, and they are sometimes used to justify confident microgram-dosing claims that the underlying data does not support. The honest summary: terminal modification is a plausible, chemically sound improvement in stability, while "better" in any broader sense — more effective, more potent, better absorbed in humans — remains largely theoretical. Better-engineered for shelf and enzymatic stability is defensible; proven superior is not.

Which should you choose?

The useful decision rule is by goal, not by hype. Cognitive performance, focus, or neuroprotection points to the Semax family; anxiety, stress, or mood points to the Selank family — and because the two are complementary, pairing them is a recognized approach rather than a contradiction. The amidate-versus-parent decision sits on top of that: the amidate offers a stability and convenience advantage with a theoretical potency upside, while the parent peptide is the better-evidenced form. Neither of those is a recommendation to use any of these compounds.

One safety point belongs in the decision rather than buried later. Because Semax is derived from an ACTH fragment, it has been flagged as potentially raising blood pressure, which is a concrete reason the choice — and especially any decision involving the more persistent amidate form — is one for a qualified clinician rather than a forum. Peptigrity does not publish dosing protocols for any of these peptides; the point here is interpretive, not instructional. The table frames the goal-based choice.

Safety, legal status, and verification

Both are generally reported well tolerated, but the same caution recurs: long-term independent safety data are limited, and the Semax-family blood-pressure flag is worth respecting, especially with the longer-acting amidate form. The legal picture is split and easy to misread. The parent peptides are registered medicines in Russia — Semax for cognitive/stroke indications, Selank for anxiety — but the amidate variants and all Western sales are grey-market "research use only" material, neither the registered drug nor a licence for human use. The rules vary by country, as covered in the legal-status guide.

Identity verification matters more here than for most peptides, precisely because of the amidate question. Since the amidate analog has a different molecular weight than its parent, an HPLC purity figure alone cannot tell you which compound is actually in the vial — a product could be highly "pure" and still not be what the label says. Mass spectrometry resolves identity by measuring that mass directly, and mislabeling between parent and amidate is a real risk worth checking for. Peptigrity aggregates independent third-party lab tests — 8,641 across the catalog as of June 2026, including 215 for Semax and 212 for Selank, with N-Acetyl Semax Amidate tracked as its own distinct compound — though these reflect voluntarily-submitted certificates rather than a random market sample. Buyers can review the lab-test records for current per-compound purity, compare sources in the shops directory, learn the workflow in how to test peptides, see the wider purity report, and — since both are nasal compounds — read the intranasal technique guide.

Frequently Asked Questions

Should I use Semax or Selank for focus?

For focus and cognitive performance, Semax is the one that fits — its profile is stimulating, and its best-documented action is upregulating BDNF and related neurotrophic signaling. Selank is the calming, anti-anxiety peptide and is not primarily a focus tool, though some researchers pair a low amount of Selank with Semax to offset overstimulation. This is not a recommendation to use either; both are unapproved research compounds, and use is a decision for a clinician.

Should I use Semax or Selank for anxiety?

Selank is the anxiety-oriented peptide of the two, acting on GABAergic and serotonergic systems with a profile the research describes as calming without the sedation or dependence associated with benzodiazepines. Semax, by contrast, is stimulating and could be counterproductive for anxiety. That said, the evidence for Selank's benzodiazepine-free profile comes largely from Russian research and has not been broadly independently replicated, so treat it as promising rather than settled.

Can you use Semax and Selank together?

They are frequently described as complementary because they work through largely different mechanisms — Semax stimulating and pro-cognitive, Selank calming — so pairing low amounts to pursue a focused-but-calm state is a recognized approach rather than a conflict. However, combining two unapproved compounds compounds the unknowns, including Semax's blood-pressure flag, and there is no established protocol. Any such decision belongs with a qualified clinician, not a forum thread.

Is N-Acetyl Semax Amidate actually better than regular Semax?

It is more chemically stable — capping both ends of the peptide genuinely slows enzymatic breakdown — but "better" beyond that is largely theoretical. The published research is mostly on regular Semax, and the popular "3–4× more potent" and "longer half-life" figures come from vendor and community sources rather than robust independent human studies. The amidate is a reasonable stability upgrade; it is not a proven improvement in effectiveness.

What is the real difference between the amidate and the parent peptide?

The amidate variant takes the same core sequence and adds an acetyl group to one end and an amide group to the other. Those terminal caps make it more resistant to the enzymes that degrade peptides, and they change its molecular weight — but they do not make it a different peptide or automatically change its mechanism. It is best understood as a stability-engineered version of the parent, not a distinct compound with its own established evidence base.

Are Semax and Selank FDA-approved?

No. Both are registered medicines in Russia, but neither is approved by the FDA or EMA for any use. Outside Russia they are sold as "research use only" compounds, and the N-acetyl amidate variants are not registered drugs anywhere — that designation is not a medical authorization or a statement of proven safety.

How do I verify I received the right compound?

Through independent third-party testing that includes both HPLC for purity and mass spectrometry for identity. Identity testing is essential here because the amidate and the parent have different molecular weights, so a purity number alone cannot confirm which one is in the vial. A certificate that shows only HPLC purity, without mass-spec identity confirmation, is incomplete for these compounds.

Does Peptigrity recommend a dose or form?

No. Semax, Selank, and their amidate variants are unapproved research compounds, and Peptigrity is an independent review platform, not a medical authority. The comparison here is educational — describing how the peptides and their forms differ and what the evidence supports — not a recommendation to use any of them. Anyone considering them should consult a licensed physician.

This article is for educational and informational purposes only and does not constitute medical advice. Semax, Selank, and their N-acetyl amidate variants are not approved by the FDA or EMA for any medical use; while registered as medicines in Russia, their evidence base is concentrated in Russian-language research with limited independent replication, and the enhanced-potency claims for the amidate variants are largely theoretical. Material sold as "research use only" is unregulated, and identity and purity vary between the parent and amidate forms. Semax has been flagged as potentially raising blood pressure. Always consult a qualified healthcare provider before making any decision about a peptide or research compound. Peptigrity is an independent review platform that does not sell, endorse, or recommend specific products or vendors, and earns no advertising, sponsorship, or affiliate revenue.